We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Finger Prick Blood Test to Enable Early Alzheimer’s Detection

By LabMedica International staff writers
Posted on 20 Nov 2024

A new approach using a quick finger prick and a few drops of blood on a card that can be sent in regular mail could make Alzheimer’s testing much more accessible worldwide. More...

The new test involves collecting one or two drops of blood from a finger prick onto a special card that immediately separates the blood cells from the plasma. After about 15 minutes, once the card has dried, it is mailed to a laboratory where high-sensitivity techniques are used for analysis. The biomarkers used in this test have been developed over a long period and have demonstrated strong performance, first in cerebrospinal fluid, then in venous blood samples, and now in blood taken from superficial vessels in the finger.

The European study, led by researchers at the University of Gothenburg (Gothenburg, Sweden), included capillary blood samples from 203 participants who took the finger prick test at one of five memory clinics across Europe. The test kits were then mailed to the neurochemistry department at the University of Gothenburg, where biomarkers for Alzheimer’s, such as pTau217, were analyzed. This test could be available for use within a few years. Another European study is already in progress to assess whether the test can be self-administered, allowing individuals to perform the finger prick and send the sample to the lab without the need for healthcare personnel.

This development comes at a time when Alzheimer’s treatments are advancing, with the drug lecanemab already approved in several countries outside the EU. Early detection is crucial for the effectiveness of these treatments. The test may also open up new opportunities for research into Alzheimer’s disease, including its genetic profile and global prevalence. However, researchers stress that this test is not intended for widespread population screening. The World Health Organization (WHO) currently advises against general screening for Alzheimer’s disease, as treatment options have traditionally been limited, making such screenings ethically questionable.

“The simple capillary blood test works almost as well as venous samples, but unlike traditional blood tests, this new test does not require transport on dry ice,” said Hanna Huber, one of the study’s authors. “This could significantly increase accessibility to Alzheimer’s testing in countries and regions lacking the infrastructure needed for high-sensitivity analyses.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.